Pharma Profits Surged 66% to $177B While the White House Sold Its Drug Pricing Deals as a Consumer Win

Trump Says His Drug Pricing Deals Will Save $529 Billion. The Drug Companies Enrolled in Them Just Made $177 Billion.

The White House says its most-favored-nation drug pricing framework will save the U.S. government $529 billion over the next decade, according to a report from the Council of Economic Advisers. The pharmaceutical companies enrolled in that framework just reported record profits: $177 billion combined, up 66 percent in a single year, according to an analysis by Senator Bernie Sanders's staff. Those two numbers do not sit comfortably in the same sentence — and the gap between them points to the part of the drug pricing debate the administration's projections leave out.

Most-favored-nation pricing, commonly abbreviated MFN, is a pricing model that requires drug companies to offer the U.S. government the lowest price they charge anywhere in the world. If a company sells a drug for $100 in Canada, it must sell the same drug to the U.S. government for $100 or less. The idea is to use the government's purchasing power to extract the same discounts that nationalized healthcare systems negotiate. The administration estimates this would save $529 billion in domestic healthcare spending over ten years, and would require manufacturers to extend MFN pricing to private insurance markets as well.

The drugs most immediately affected by that pricing pressure include GLP-1s — a class of medications that mimic the GLP-1 hormone to regulate blood sugar and appetite. Wegovy, Ozempic, Mounjaro, and Zepbound are the best-known examples. They are effective. They are also expensive: list prices run between $900 and $1,300 per month without insurance, and even the White House's own projections acknowledge that GLP-1 coverage under existing programs would pull tens of billions from the Medicare Trust Fund.

The administration is asking Congress to make the framework permanent, to codify it beyond executive action, and to trust that the savings will materialize. The Congressional Budget Office estimated in October 2024 that a similar framework could reduce prescription drug prices by roughly 5 percent — a real but modest signal that the mechanism can work, and a far cry from $529 billion in projected savings.

The gap between those two numbers is not just a budget projection problem. It is a pipeline problem.

The structural incentive is direct: pharmaceutical companies fund R&D through revenues generated in markets where they can set prices. The U.S. market, where list prices run far above what European and Canadian governments pay for identical drugs, is the most lucrative market in the world for these companies. MFN pricing would not just reduce what patients pay at the pharmacy counter — it would compress the revenues that fund the fifteen-year, multi-billion-dollar pipeline that produces new medicines. The question is not whether that pipeline survives. It is which parts of it survive, and which patients depend on the parts that don't.

Pharmaceutical companies use revenue from markets where they can charge high prices to fund the research that produces new drugs. Academic estimates suggest that for every 10 percent reduction in U.S. drug revenues, the number of new medicines entering clinical development drops by 2.5 to 15 percent — a range that reflects genuine uncertainty about how sensitive innovation is to pricing, but not about the direction. A recent analysis from the Becker Friedman Institute at the University of Chicago estimated that MFN pricing could produce reductions in new drug development ten times larger than the CBO's models implied. The mechanism is straightforward: lower expected revenues mean lower expected returns, which means less investment in drugs that take fifteen years and billions of dollars to develop.

The effects would not fall evenly. Orphan drugs — medications developed for rare diseases that affect small patient populations — depend on high per-patient pricing to generate any return at all. Academic research on pharmaceutical innovation notes that when revenues decline, R&D investment follows with a compounding effect in rare disease, where the pool of potential patients is too small to support development at lower price points. A drug that might treat five thousand patients worldwide cannot be funded the way a diabetes drug serving fifty million can.

Whether that tradeoff is worth making — whether the savings on existing drugs justify fewer new ones — is a genuine policy question. The administration has not engaged with it directly. Its $529 billion estimate assumes Congress acts, the deals hold, legal challenges fail, and the pricing framework produces the savings its model projects. It does not account for what happens to the drug pipeline if the model works exactly as designed.

The Pfizer deal has not been finalized. Wyden and seventeen Senate Democrats have asked the administration to disclose the terms. Public Citizen has sued under FOIA to obtain them. The public cannot verify what the deals actually require — what loopholes exist, whether the MFN price guarantees are meaningful, or how the framework handles drugs still in development.

What is documented is that the fifteen companies enrolled in the MFN framework reported $177 billion in combined profits over the period the administration was projecting $529 billion in savings. The two numbers are not mutually exclusive. Pharma can save money for the government and still make more money than ever. That is, broadly, how the industry has always worked.

The White House's own projections acknowledge that GLP-1 coverage under existing programs would pull tens of billions from the Medicare Trust Fund. The question the administration does not answer is which drugs get invented in a world where the math works — and which patients get left behind if it does.